Ordenar

Buscar

01/11/2025 Prophylactic Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement
Fischer, Q, Nombela-Franco, L, Muntané-Carol, G, Veiga, G, Regueiro, A, Nazif, T, Serra, V, Asmarats, L, Ribeiro, HB, Latib, A, Poulin, A, Cheema, AN, Tirado-Conte, G, Gomez-Hospital, JA, Ongay, AG, Gabani, R, Arzamendi, D, Brener, M, Calabuig, A, Scotti, A, Gelain, MAS, Labinaz, M, Cepas-Guillén, P, Côté, M, del Portillo, JH, Philippon, F, Rodés-Cabau, J. Prophylactic Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement. JACC-Clinical Electrophysiology. 2025; 11(11)DOI:10.1016/j.jacep.2025.07.028. PMID:40965381. IF:7.700(Q1/1D).
01/11/2025 Refractory congestion following successful pericardiocentesis for cardiac tamponade: effusive-constrictive pericarditis caused by Cutibacterium acnes
Santaló-Corroy, M, Triguero-Llonch, L, Fernández-Martinez, J, Arias-Pinilla, JP, Ferrer-Menéndez, M, Bonet-Basiero, A. Refractory congestion following successful pericardiocentesis for cardiac tamponade: effusive-constrictive pericarditis caused by Cutibacterium acnes. REVISTA ESPANOLA DE CARDIOLOGIA. 2025; 78(11)DOI:10.1016/j.rec.2025.06.009. PMID:40812677. IF:4.900(Q1/2D).
01/11/2025 Sex differences in mitral regurgitation anatomy and outcomes of transcatheter edge-to-edge repair
Li, CHP, Asmarats, L, van Roessel, AM, Capellades, H, Fernández-Peregrina, E, Arzamendi, D. Sex differences in mitral regurgitation anatomy and outcomes of transcatheter edge-to-edge repair. REVISTA ESPANOLA DE CARDIOLOGIA. 2025; 78(11)DOI:10.1016/j.rec.2025.01.018. PMID:39938677. IF:4.900(Q1/2D).
01/11/2025 Clinicopathological and molecular features of recurrence in ctDNA-negative resected colorectal cancer
Beltran, JS, Pérez, MARSM, Manrique, ACV, Cullell, BM, Munoz, MN, Mateo, FJP, Riera, P, Fuste, V, Fumagalli, C, Szafranska, J, Catasus, L, Gonzalez, A, Paez, D. Clinicopathological and molecular features of recurrence in ctDNA-negative resected colorectal cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1344. PMID:. IF:65.400(Q1/1D).
01/11/2025 Methotrexate-Induced Gouty Arthritis in Psoriatic Patient
Carmona-Rocha, E, Torné, CD, Alonso, AML, Puig, L. Methotrexate-Induced Gouty Arthritis in Psoriatic Patient. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2024.02.050. PMID:40615030. IF:(Q/D).
01/11/2025 Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial
Ballesteros, PA, García-Carbonero, I, Gonzalez, EE, Marin, AP, Lorente, D, de Liaño, AG, Ortega, EM, Colomo, LJ, Puente, J, Gonzalez, I, Calvo, OF, Palacios, GA, Mendizabal, I, Navarro, EP, Domínguez, JID, Esteban-Villarrubia, J, Billalabeitia, EG, Oria, GAD. Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3696. PMID:. IF:65.400(Q1/1D).
01/11/2025 Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry
España, MAG, Calle, SG, Flores, EG, Sosa, MM, Tocino, RV, Plazas, JG, Monteagudo, RF, Aguilera, MJS, Herrero, MDRM, Gargia, TG, Zafra, GM, Arévalo, MA, Orozco, EJ, Manrique, ACV, Alfonso, PG, Montes, AF, Ninerola, RQ, de Castro, EM, Verdaguer, H, García, RV. Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1362. PMID:. IF:65.400(Q1/1D).
01/11/2025 Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment
Ahrens, M, Haanen, JBAG, Albiges, L, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Rottey, S, Floercken, A, Rodriguez, CS, Rey, JPM, Burkholder, I, Hartmann, A, Bergmann, L. Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3211. PMID:. IF:65.400(Q1/1D).